...
机译:一种多中心,开放标签相3研究血友病A与抑制剂血友病A的eMicizumab预防
Univ Southern Calif Keck Sch Med Childrens Hosp Los Angeles 4650 Sunset Blvd Mail Stop 54 Los;
Great Ormond St Hosp Sick Children London England;
Genentech Inc San Francisco CA 94080 USA;
Emory Univ Childrens Healthcare Atlanta Atlanta GA 30322 USA;
Univ Bonn Inst Expt Hematol &
Transfus Med Bonn Germany;
Univ Autonoma Madrid Hosp Univ La Paz Madrid Spain;
Univ Witwatersrand Charlotte Maxeke Johannesburg Acad Hosp NHLS Johannesburg South Africa;
Bloodworks Northwest Seattle WA USA;
Univ Colorado Sch Med Hemophilia &
Thrombosis Ctr Anschutz Med Campus Aurora CO USA;
F Hoffmann La Roche Ltd Basel Switzerland;
Genentech Inc San Francisco CA 94080 USA;
Genentech Inc San Francisco CA 94080 USA;
F Hoffmann La Roche Ltd Basel Switzerland;
Genentech Inc San Francisco CA 94080 USA;
Nara Med Univ Dept Pediat Kashihara Nara Japan;
Fdn Ist Ricovero &
Cura Carattere Sci IRCCS Ca Gr Osped Maggiore Policlin Angelo Bianchi Bonomi;
机译:一种多中心,开放标签相3研究血友病A与抑制剂血友病A的eMicizumab预防
机译:在先前治疗的严重血友病患者中,3B相,开放标签,多中心,rUroiocog Alfa Pegol对预防血糖的疗效和安全结果。
机译:每2周或每4周皮下注射emicizumab在儿科血友病患者中没有抑制剂:日本的多中心,开放标签研究(Hohoemi学习)
机译:血友病A和高滴度抑制剂的三名患者的短时预防
机译:充满胶原细丝的新型胶原蛋白导管治疗周围神经损伤患者的疗效和安全性:一项多中心,对照,开放标签的临床试验
机译:艾米珠单抗在有或没有抑制剂的血友病A患者中进行的1/2期研究的长期安全性和有效性
机译:用抑制剂血友病A患儿Emicizumab预防的多中心开放标签阶段3研究